Leadership through partnership Learning through authenticity Courage through knowledge Enthusiasm through belonging Perseverance through desire

Xentria engaged Meitheal in a licensing agreement for the commercialization of XTMAB-16, a clinical-stage anti-TNF monoclonal antibody, to address the unmet medical needs of sarcoidosis patients. XTMAB-16 is currently under clinical investigation.

Learn More

We are a biotech company building authentic life-sciences partnerships to guide innovative drug and intellectual property development from early concepts through clinical development and towards commercial launch.

Who We Are

What We Do

We reinvent how life-sciences partnerships can deliver adaptive approaches to ambitious drug innovation for improved patient outcomes.

Guiding Your Concept

Our Portfolio

Our current pipeline represents how our partnerships guide ambitious developers through challenging drug projects.

View Pipeline

XTMAB-16

Discover how tenacity, expertise, and partnerships built on trust drove Xentria’s development of an Investigational New Drug (IND) candidate aimed to suppress the physiologic response tumor necrosis factor (TNF).

View the Journey

Life at Xentria

We are a growing team of resourceful innovators who embrace those with the desire to engage, adapt, serve and solve. Find out how you can apply your talents to advance the development of needed drugs with challenging profiles. The results of your work are noticed, and you can see the difference they make.

Be Part of Our Team